The Emperor of All Maladies

The beeper went off as Siddhartha Mukherjee was heading into Massachusetts General Hospital. Ten months into his oncology fellowship, he already felt drained. The death around him had become routine. But this call was different. A new patient had arrived—a thirty-one-year-old kindergarten teacher named Carla Reed, mother of three young children.

She came in with headaches, strange bruising, white gums, and exhaustion that wouldn't lift. Her blood tests told the story: five times the normal number of white blood cells, and ninety-five percent of them were blasts—immature cells that could never mature into functioning lymphocytes. They were useless. Her bone marrow had been taken over. Her red blood cell count had dropped so low her blood could barely carry oxygen.

Mukherjee sat down with Carla and delivered the news. She likely had acute lymphoblastic leukemia, or ALL—a cancer more common in children than adults. It was often curable. She would start chemotherapy immediately. Her chance of being cured: thirty percent.

Carla looked at him. Thirty percent. She had three children. She had a life. She had walked into this hospital expecting treatment and instead received a probability.

Nothing in Mukherjee's training could have prepared him for this moment. He thought of Aleksandr Solzhenitsyn's novel *Cancer Ward*, where the protagonist experiences the erasure of his identity upon diagnosis. Cancer did that to people. It consumed everything else. He felt stunned, almost to the point of incoherence, about the decisions he had to make each day.

This encounter—Carla's face, her fear, her thirty-percent chance—drove Mukherjee to understand something deeper. He knew the biology. Cancer was the uncontrolled growth of a single cell. But that description felt hollow in the face of a young mother's diagnosis. He wanted to know the full story: where cancer came from, how we had fought it, and why, after thousands of years, we still struggled to defeat it.

The book he wrote became a biography of cancer itself—a 4,000-year history of a disease that is intimately tied to our own biology. Cancer cells, Mukherjee writes, grow faster, adapt better. "They are more perfect versions of ourselves." That's the terrifying truth: cancer doesn't come from outside. It emerges from our own cells, our own genome. The enemy is us.

Mukherjee describes cancer as a clonal disease—all the cancer cells in a patient's body descend from a single rogue cell. But it's also an evolving disease. Each generation of cancer cells is slightly different from the one before. Mutations accumulate. The cancer adapts. It perverts the Darwinian process of evolution and natural selection, turning it against the host.

This is what makes cancer so insidious. Normal growth and malignant growth are so intertwined that separating them is immensely difficult. As we seek immortality, so does the cancer cell. Preventing its growth means interfering with our own most fundamental biology.

Carla's treatment began immediately. Three rounds of chemotherapy: induction, intensification, maintenance. After the first round, her white blood cell count would plummet. She would have no immune system. If she didn't go into remission, the treatment would intensify. If she did, she'd still need two years of maintenance therapy. Doctors would have to inject chemicals into her spinal fluid to reach her brain.

She retreated into herself. She shuffled around the hospital like a zombie, enduring endless blood tests, spinal taps, bone marrow biopsies. The drugs meant to save her made her sick. Her life became the hospital. The outside world faded.

Mukherjee began to trace the long arc of this disease. He found its first recorded descriptions in ancient Egypt—the Edwin Smith Papyrus from 2500 BCE, where the physician Imhotep described "bulging masses" of breast cancer and wrote that there was no cure. In 500 BCE, the Persian queen Atossa suffered from an inflammatory mass in her breast and withdrew into quarantine until a Greek slave convinced her to let him cut off the lump. She survived. Cancer, even then, changed the course of history.

The Greeks gave cancer its name. Hippocrates used the word *karkinos*—crab—because the tumor surrounded by swollen blood vessels reminded him of a crab. Another Greek word, *onkos*, meaning "a mass," would give rise to the word "oncology." The Greeks believed the body was composed of four humors: blood, yellow bile, black bile, and phlegm. Galen thought cancer resulted from an excess of black bile. This theory held medicine in its grip for centuries.

For most of human history, there was no effective treatment. People died. The disease was rare in the ancient world because people simply didn't live long enough to develop it. Other diseases—smallpox, tuberculosis, infections—killed them first. But as public health improved and lifespans lengthened, cancer emerged as the disease to beat.

By the 1940s, cancer had become the leading cause of death in America after heart disease. The fight against it had barely begun. Surgeons cut out tumors where they could. Radiation burned them away. But for cancers that had spread—like Carla's leukemia—these local treatments were useless.

Mukherjee realized that to understand Carla's disease, he had to understand its history. The war against cancer was not a new war. It had been fought for millennia, with varying strategies, shifting theories, and mixed results. Each generation thought it had found the answer—surgery, radiation, chemotherapy—only to discover that cancer adapted, retreated, and returned.

What made this moment different? What made Carla's thirty-percent chance possible where earlier patients had none?

The answer lay in the laboratory of Sidney Farber, a pathologist at Boston Children's Hospital who, in 1947, had waited for a shipment of a chemical called aminopterin. He believed he could treat leukemia with it. The medical establishment thought he was crazy. Leukemia was a medical orphan, abandoned by surgeons and internists. But Farber persisted. He injected aminopterin into a two-year-old boy named Robert Sandler, whose blood was filled with leukemic blasts and whose spleen was enlarged. The response was marked. The boy's white cell count stopped rising, then dropped. His spleen shrank. His energy and appetite returned. For a while, he was in remission—a state unprecedented in the treatment of leukemia.

The remission didn't last. Robert Sandler died in 1948. But Farber had proven something crucial: cancer could be treated with chemicals. He had thrown down a gauntlet. It was up to an entire generation of doctors and scientists to pick it up.

Mukherjee's book traces that generation's work—the political campaigns, the scientific breakthroughs, the desperate gambles, the heartbreaking failures, and the slow, grinding progress that turned childhood leukemia from a death sentence into a survivable disease for many patients.

Carla Reed was one of those survivors. On a warm morning in August 2005, Mukherjee called her to say her cancer was in remission. Five years later, he visited her at her house. She told him that being sick had become her new normal. Treatment had become her life for as long as she needed it.

But the war wasn't over. Cancer had simply retreated. It would adapt again. New treatments would be needed. New battles would be fought.

What if Carla's cancer returned? What if the cells that survived her chemotherapy learned to resist the drugs? What if the thirty percent who were cured were the lucky ones, and the seventy percent who weren't were simply outrun by a disease that evolved faster than medicine could keep up?